TrialCancer communications (London, England)2022

XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX).

Xiao-Dong Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.